The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
Open accessAbstract
BACKGROUND: The objectives of this study were to evaluate the association between varicella-zoster virus (VZV)-specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ morbidity and to compare immune responses to HZ and zoster vaccine. METHODS: In 981 elderly persons who developed HZ during a zoster vaccine efficacy trial (321 vaccinees and 660 placebo recipients) and 1362 without HZ (682 vaccinees and 680 placebo recipients), CMI was measured by VZV responder cell frequency and interferon-gamma enzyme-linked immunospot, and antibodies were measured by VZV enzyme-linked immunosorbent assay against affinity-purified VZV glycoproteins (gpELISA). RESULTS: Robust VZV CMI at HZ onset correlated with reduced HZ morbidity, whereas VZV gpELISA titers did not. Three weeks after HZ onset, gpELISA titers were highest in those with more severe HZ and were slightly increased in placebo recipients (compared with zoster vaccine recipients) and in older individuals. VZV CMI responses to HZ were similar in zoster vaccine and placebo recipients and were not affected by demographic characteristics or antiviral therapy, except for responder cell frequency at HZ onset, which decreased with age. When responses to zoster vaccine and HZ could be compared, VZV CMI values were similar, but antibody titers were lower. CONCLUSIONS: Higher VZV CMI at HZ onset was associated with reduced HZ severity and less postherpetic neuralgia. Higher antibody titers were associated with increased HZ severity and occurrence of postherpetic neuralgia. HZ and zoster vaccine generated comparable VZV CMI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Levin, M. J., Smith, J. G., Kaufhold, R. M., Barber, D., Hayward, A. R., Chan, C. Y., Chan, I. S. F., Li, D. J. J., Wang, W., Keller, P. M., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/379048 · Cited by 314
Self-citation
Cited by
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Molecular mechanisms of varicella zoster virus pathogenesis
Zerboni, L., Sen, N., Oliver, S. L., & Arvin, A. M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3215 · Cited by 477
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Schmader, K. E., Levin, M. J., Gnann, J. W., McNeil, S. A., Vesikari, T., Betts, R. F., Keay, S., Stek, J. E., Bundick, N. D., Su, S.-C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir970 · Cited by 430
Self-citationNomenclature for Immune Correlates of Protection After Vaccination
Plotkin, S. A., & Gilbert, P. B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis238 · Cited by 347
Contributions of humoral and cellular immunity to vaccine-induced protection in humans
Amanna, I. J., & Slifka, M. K. (2011) · Virology · doi:10.1016/j.virol.2010.12.016 · Cited by 263
Metadata
- Authors
- Weinberg, A., Zhang, J. H., Oxman, M. N., Johnson, G. R., Hayward, A. R., Caulfield, M. J., Irwin, M. R., Clair, J., Smith, J. G., Stanley, H., Marchese, R. D., Harbecke, R., Williams, H. M., Chan, I. S. F., Arbeit, R. D., Gershon, A. A., Schödel, F., Morrison, V. A., Kauffman, C. A., Straus, S. E., Schmader, K. E., Davis, L. E., Levin, M. J., & the US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10
- Volume
- 200
- Issue
- 7
- Pages
- 1068-1077
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2165687705
- Cited by
- 271
- References
- 3
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. https://app.cochat.ai/papers/10.1086/605611
- The paper
- Weinberg, A., Zhang, J. H., Oxman, M. N., Johnson, G. R., Hayward, A. R., Caulfield, M. J., Irwin, M. R., Clair, J., Smith, J. G., Stanley, H., Marchese, R. D., Harbecke, R., Williams, H. M., Chan, I. S. F., Arbeit, R. D., Gershon, A. A., Schödel, F., Morrison, V. A., Kauffman, C. A., . . . the US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. (2009). Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1086/605611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.